![Lior Shaltiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lior Shaltiel
Directeur Général chez
NUREXONE BIOLOGIC INC.
Fortune : 628 425 $ au 31/08/2026
Profil
Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC 1,67 % | 27/11/2025 | 1 575 000 ( 1,67 % ) | 628 425 $ | 31/08/2026 |
Postes actifs de Lior Shaltiel
| Sociétés | Poste | Début |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Directeur Général | 01/04/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Directeur Général | 01/04/2021 |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/10/2015 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
NurExone Biologic, Inc.
 NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
